Long term efficacy, safety and tolerability of Tildrakizumab in epileptic patient with psoriasis and eczema

• Päätekijät: Nicoletta Bernardini (Tekijä), Nevena Skroza (Tekijä), Giovanni Rossi (Tekijä), Alessandra Mambrin (Tekijä), Ersilia Tolino (Tekijä), Federica Marraffa (Tekijä), Martina Caviglia (Tekijä), Antonio Di Guardo (Tekijä), Salvatore Volpe (Tekijä), Ilaria Proietti (Tekijä), Concetta Potenza (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: PAGEPress Publications, 2022-10-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Psoriasis is a chronic inflammatory disease which mostly affects skin. Tildrakizumab is a specific anti‐interleukin‐23p19 monoclonal antibody approved for the treatment of plaque psoriasis in adults. Herein, we report about a patient who came to our attention for a moderate-to-severe plaque psoriasi...